Ion Biotechnology®, a registered trademark of Grupo Ion Biotech, S.A.P.I. de C.V., represents more than just a brand—it symbolizes a movement toward transformative medical innovation. As the parent company of Ion Biotechnology México, S.A. de C.V., Grupo Ion Biotech holds a pivotal role in developing and commercializing advanced health solutions built on proprietary IBAL technology. With nonprovisional patent pending status in Mexico, Ion Biotechnology® is fully authorized to develop pharmaceutical, OTC, and nutritional products using its groundbreaking formulations.
Under its exclusive license, Ion Biotechnology México, S.A. de C.V. maintains the rights to contract, manufacture, and sublicense these products across Mexico, Central America, and South America. This agreement secures its leadership in these regions and allows for the expansion and protection of intellectual property across new innovations derived from IBAL formulations.
IBAL, short for Ion Biotechnology Aqueous Ligands, is a cutting-edge scientific platform rooted in the coordination chemistry of essential ions. The technology is built on ligand-stabilized redox complexes incorporating zinc, copper, magnesium, sulfur, and hydrogen in highly bioavailable forms. These ions are essential for numerous metabolic and regenerative processes in the human body.
Unlike traditional single-action products, IBAL formulations are multifunctional, with proven antimicrobial, anti-inflammatory, antioxidant, and wound-healing properties. This multifunctionality sets IBAL-based products apart in the global market, particularly in the fight against healthcare-associated infections (HAIs), antimicrobial resistance, and chronic wound conditions.
At the core of Ion Biotechnology® is a scientific vision that blends biology, chemistry, and medicine. The technology was developed through rigorous preclinical and clinical evaluations, including formal Phase I safety trials, oxidative stress studies, and antimicrobial challenge testing against pathogens like MRSA, A. brasiliensis, and SARS-CoV-2.
The company has created a strong collaborative ecosystem, bringing together a multidisciplinary team of molecular engineers, biomedical researchers, pharmacists, physicians, and product developers. This approach has been central to delivering breakthrough formulations such as Ion Gel ZCM-25®, a 25% concentration IBAL-based gel used widely in post-surgical recovery, diabetic foot ulcers, and hospital infection prevention.
Ion Biotechnology® has taken a regional leadership role, focusing on Latin America and building global distribution partnerships through its alliance with Ionic Alliance Group and platforms such as 2+ Cations®, a multilingual cloud-based portal offering training, clinical studies, and product support.
Each innovation under the Ion Biotechnology® trademark is manufactured under cGMP standards and designed for safe, effective, and scalable healthcare applications. As it grows, it remains committed to advancing cost-effective and clinically validated solutions to meet the world’s most pressing health challenges.
In a time when global healthcare systems are stretched thin, Ion Biotechnology® and its IBAL technology offer a fresh, science-backed approach to healing and prevention. It is not just about the chemistry—it’s about changing lives, one innovation at a time.
